A detailed history of Thoroughbred Financial Services, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Thoroughbred Financial Services, LLC holds 786 shares of BGNE stock, worth $178,194. This represents 0.02% of its overall portfolio holdings.

Number of Shares
786
Holding current value
$178,194
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

BUY
N/A
786 New
786 $267,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Thoroughbred Financial Services, LLC Portfolio

Follow Thoroughbred Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.